

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/079153 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 7/00 (2006.01)
C07K 14/00 (2006.01)

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2022/081018

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

07 November 2022 (07.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/277,049 08 November 2021 (08.11.2021) US
63/277,052 08 November 2021 (08.11.2021) US
63/404,008 06 September 2022 (06.09.2022) US
63/404,068 06 September 2022 (06.09.2022) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **HOOKIPA BIOTECH GMBH** [AT/AT];
Helmut-Qualtinger-Gasse 2, 1030 Wien (AT).

(72) Inventors: **LAUTERBACH, Henning**; Adolf-Sturm-
Strasse 20b, 82211 Herrsching am Ammersee (DE).
LAMPERT, Jörg Christoph; Thérèse Schwartzestraat
113, 2597 XK Den Haag (NL). **HABBEDDINE,
Mohamed**; Spiegelbergstrasse 24, 4059 Basel (CH).
RAGUZ, Josipa; Urschenboeckgasse 3/35, 1030 Wien
(AT). **SCHIPPERS, Timo**; Bayerngasse 3/7, 1030
Wien (AT). **SCHMIDT, Sarah**; Eroicagasse 7/5/2,
1190 Wien (AT). **AHMADI-ERBER, Sarah**; Vorgarten-
straße 145-157/1/6, 1020 Wien (AT). **ROSSKOPF, San-
dra**; Wagner-Schönkirch-Gasse 31, 2232 Deutsch-Wagram
(AT). **ORLINGER, Klaus**; Schätzgasse 4/1, 1190 Wien
(AT). **MATUSHANSKY, Igor**; 2517 East 64th St, Brook-
lyn, New York 11234 (US).

(74) Agent: **JONES DAY**; Prinzregentenstr. 11, 80538 Munich
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

(54) Title: MODIFIED ARENAVIRUS PARTICLES EXPRESSING MUTANT KRAS, MUTATED CANCER DRIVER GENE, OR
TUMOR-ASSOCIATED ANTIGEN AS CANCER IMMUNOTHERAPIES

(57) Abstract: The invention relates to genetically modified arenaviruses suitable for the treatment of neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus, wherein the arenavirus has been engineered to include a nucleotide sequence encoding one or more antigenic fragment(s) of mutant KRAS alone or to further include a nucleotide sequence encoding one or more antigenic fragment(s) of a mutated cancer driver gene (e.g., a mutant TP53) or a tumor-associated antigen.



WO 2023/079153 A1